gopubmed logo
 
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 07 Jul 2015.

V-raf murine sarcoma viral oncogene homolog B1

BRAF
This gene encodes a protein belonging to the raf/mil family of serine/threonine protein kinases. This protein plays a role in regulating the MAP kinase/ERKs signaling pathway, which affects cell division, differentiation, and secretion. Mutations in this gene are associated with cardiofaciocutaneous syndrome, a disease characterized by heart defects, mental retardation and a distinctive facial appearance. Mutations in this gene have also been associated with various cancers, including non-Hodgkin lymphoma, colorectal cancer, malignant melanoma, thyroid carcinoma, non-small cell lung carcinoma, and adenocarcinoma of lung. A pseudogene, which is located on chromosome X, has been identified for this gene. [provided by RefSeq, Jul 2008] (from NCBI)
Top mentioned proteins: KRAS, CAN, Raf, HAD, EGFR
Papers using BRAF antibodies
Induction of autophagy and inhibition of melanoma growth in vitro and in vivo by hyperactivation of oncogenic BRAF
Supplier
Pal Soumitro, In PLoS ONE, 2009
... All primary antibodies were purchased from Cell Signaling Technology except the following: anti-BRAF from Santa Cruz Biotechnology, anti-CRAF from BD Biosciences, ...
RET/PTC rearrangements in thyroid nodules: studies in irradiated and not irradiated, malignant and benign thyroid lesions in children and adults
Supplier
LiVolsi Virginia A et al., In CytoJournal, 2000
... The amplified products were electrophoresed on a 1.2% gel at 110 V for 1.5 hours and the BRAF bands (~220 bp) were cut using sterile blade and purified using Qiagen Gel Extraction Kit (Hilden, ...
A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)
Supplier
Brinker Achim et al., In Current Chemical Genomics, 1993
... Unconjugated B-Raf antibody was from Santa Cruz Biotechnology (sc-5284), pMEK1/2 antibody from ...
Papers on BRAF
KRAS(G12D)-mediated oncogenic transformation of thyroid follicular cells requires long-term TSH stimulation and is regulated by SPRY1.
New
Shi et al., Riyadh, Saudi Arabia. In Lab Invest, 06 Aug 2015
The expression of SPRY1, a negative regulator of receptor tyrosine kinase (RTK) signaling, was analyzed in both KRAS(G12D)-and BRAF(V600E)-induced thyroid cancers.
A Synergistic Interaction between Chk1- and MK2 Inhibitors in KRAS-Mutant Cancer.
New
Impact
Reinhardt et al., Köln, Germany. In Cell, 02 Aug 2015
Here, we perform a cell-line-based screen and identify strong synergistic interactions between cell-cycle checkpoint-abrogating Chk1- and MK2 inhibitors, specifically in KRAS- and BRAF-driven cells.
Double stranded promoter region of BRAF undergoes to structural rearrangement in nearly physiological conditions.
New
Sissi et al., Italy. In Febs Lett, 01 Aug 2015
Herein, we focused on a 30 bases sequence located upstream of the transcription start site of BRAF (Braf-176) that contains 80% of guanines.
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 Signaling.
New
Chen et al., Atlanta, United States. In Mol Cell, 01 Aug 2015
Here we demonstrate a "synthetic lethal" interaction between oncogenic BRAF V600E and a ketogenic enzyme 3-hydroxy-3-methylglutaryl-CoA lyase (HMGCL).
Rectal and colon cancer: Not just a different anatomic site.
New
Hospers et al., Groningen, Netherlands. In Cancer Treat Rev, 28 Jul 2015
Moreover, they harbor a different composition of drug targets, such as v-raf murine sarcoma viral oncogene homolog B (BRAF), which is preferentially mutated in proximal colon cancers, and the epidermal growth factor receptor (EGFR), which is prevalently amplified or overexpressed in distal colorectal cancers.
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial.
New
Impact
Daud et al., Los Angeles, United States. In Lancet Oncol, 23 Jul 2015
BACKGROUND: Patients with melanoma that progresses on ipilimumab and, if BRAF(V600) mutant-positive, a BRAF or MEK inhibitor or both, have few treatment options.
Genomic Classification of Cutaneous Melanoma.
New
Impact
Cancer Genome Atlas Network et al., In Cell, 18 Jul 2015
We establish a framework for genomic classification into one of four subtypes based on the pattern of the most prevalent significantly mutated genes: mutant BRAF, mutant RAS, mutant NF1, and Triple-WT (wild-type).
[New targets and new drugs in thoracic oncology].
Review
New
Mazieres et al., Toulouse, France. In Rev Mal Respir, 12 Jul 2015
However, new molecular targets have been highlighted recently including BRAF mutations, HER2 or PI3K, new translocations such as ROS1 or KIF5B-RET.
BRAF inhibitors: the current and the future.
Review
New
Zhang, New York City, United States. In Curr Opin Pharmacol, 10 Jul 2015
UNASSIGNED: The introduction of BRAF inhibitors (BRAFi), vemurafenib and dabrafenib, revolutionized BRAFV600-mutated metastatic melanoma treatment with improved response rate and overall survival compared to standard chemotherapy.
Different treatment strategies and molecular features between right-sided and left-sided colon cancers.
Review
New
Yuan et al., Hangzhou, China. In World J Gastroenterol, 07 Jul 2015
With respect to carcinogenesis mechanisms, RCC is associated with known gene types, such as MMR, KRAS, BRAF, and miRNA-31, while LCC is associated with CIN, p53, NRAS, miRNA-146a, miRNA-147b, and miRNA-1288.
Gaining momentum: New options and opportunities for the treatment of advanced melanoma.
Review
New
Hoeller et al., Lausanne, Switzerland. In Cancer Treat Rev, 04 Jul 2015
A greater understanding of the epidemiology and biology of disease has underpinned the development of newer therapies, including six agents that have been approved in the EU, US and/or Japan: a cytotoxic T-lymphocyte antigen-4 inhibitor (ipilimumab), two programmed cell death-1 receptor inhibitors (nivolumab and pembrolizumab), two BRAF inhibitors (vemurafenib and dabrafenib) and a MEK inhibitor (trametinib).
Epigenetic activation of a cryptic TBC1D16 transcript enhances melanoma progression by targeting EGFR.
New
Impact
Esteller et al., Barcelona, Spain. In Nat Med, 01 Jul 2015
We also found that epigenetic reactivation of TBC1D16-47KD is associated with poor clinical outcome in melanoma, while conferring greater sensitivity to BRAF and MEK inhibitors.
[DNA mismatch repair and BRAF status in colorectal cancer: Interest for the therapeutic management?].
Review
New
André et al., Paris, France. In Bull Cancer, 30 Jun 2015
CMS1 is enriched for CRC with deficient DNA mismatch repair system (dMMR) and tumors with mutated BRAF.
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
New
Impact
Mills et al., Houston, United States. In J Clin Oncol, 26 Jun 2015
Of 230 patients with PIK3CA/AKT1/PTEN/BRAF mutations that returned for therapy, 116 (50%) received a genotype-matched drug.
Variations of BRAF mutant allele percentage in melanomas.
New
Emile et al., Boulogne-Billancourt, France. In Bmc Cancer, Dec 2014
BACKGROUND: BRAF mutations are present in 40 % of human skin melanomas.
The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway.
GeneRIF
Pritchard et al., Leicester, United Kingdom. In Genes Dev, 2012
endogenous expression of (L597V)Braf leads to approximately twofold elevated Braf kinase activity and weak activation of the Mek/Erk pathway
BRAF duplications and MAPK pathway activation are frequent in gliomas of the optic nerve proper.
GeneRIF
Eberhart et al., Baltimore, United States. In J Neuropathol Exp Neurol, 2012
The results of this study supported an important role for BRAF duplication and MAPK pathway activation in gliomas of the optic nerve proper.
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis.
Review
GeneRIF
Xing et al., Baltimore, United States. In Medicine (baltimore), 2012
Thus, in this meta-analysis, the BRAF mutation in PTC was significantly associated with PTC recurrence, lymph node metastasis, extrathyroidal extension, and advanced stage AJCC III/IV.
KRAS and BRAF mutations in Serbian patients with colorectal cancer.
GeneRIF
Jankovic et al., Belgrade, Serbia. In J Buon, 2012
the spectrum and frequency distribution of the identified KRAS and BRAF mutations in Serbian patient with colorectal cancer are in good accordance with literature data.
A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
GeneRIF
Ozkinay et al., İzmir, Turkey. In Genet Couns, 2011
Cardio-facio-cutaneous syndrome is caused by heterogeneous mutations in BRAF gene.
share on facebooktweetadd +1mail to friends